WASHINGTON — A phase 2 study found that ST-100, a collagen mimetic peptide, could provide a new avenue for treatment of dry eye disease, according to a presenter at the American Society of Cataract and Refractive Surgery meeting.
Edward J. Holland, MD, said PolyCol (Stuart Therapeutics) looks to address a new therapeutic target in dry eye disease.
“PolyCol is a collagen mimetic peptide that directly repairs damaged helical collagen,” he said. “This can upregulate inflammatory modulation, epithelial cell replacement and growth, and collagen production, while